MASI: Masimo Corporation Stock

by  •  • Comments Off on MASI: Masimo Corporation Stock

SIC 3845 – Electromedical and Electrotherapeutic Apparatus

Valuation
Market Cap ($M) 6,581.02
Enterprise Value ($M) 7,299.42
Book Value ($M) 1,365.20
Book Value / Share 25.72
Price / Book 4.82
NCAV ($M) -426.90
NCAV / Share -8.04
Price / NCAV -15.42

Profitability (mra)
Return on Invested Capital (ROIC) 0.03
Return on Assets (ROA) 0.03
Return on Equity (ROE) 0.06

Liquidity (mrq)
Quick Ratio 1.31
Current Ratio 2.31

Balance Sheet (mrq) ($M)
Current Assets 1,165.60
Assets 2,957.70
Liabilities 1,592.50
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 2,048.10
Operating Income 164.30
Net Income 81.50
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 94.10
Cash from Investing -81.20
Cash from Financing -57.10

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-09 13D/A Politan Capital Management LP 8.90 0.00
02-14 13G/A Kiani Joe E 9.20 -0.04
02-13 13G/A Vanguard Group Inc 9.05 -1.53
02-09 13G/A Fmr Llc 13.11 26.96
01-24 13G/A BlackRock Inc. 10.70 -5.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 30, 2024 ☐ TRANSITION REPORT P
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1 )
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K
2023-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 1, 2023 ☐ TRANSITION REPORT PUR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-17 179,902 363,603 49.48
2024-05-16 77,575 208,251 37.25
2024-05-15 78,368 1,086,979 7.21
2024-05-14 70,860 661,518 10.71
2024-05-13 55,380 752,974 7.35

(click for more detail)

Similar Companies
ISRG – Intuitive Surgical, Inc. LIVN – LivaNova PLC
LUNG – Pulmonx Corporation MMSI – Merit Medical Systems, Inc.
NARI – Inari Medical, Inc.


Financial data and stock pages provided by
Fintel.io